Medtronic (MDT) stock jumps after beating Q4 revenue expectations, driven by strong growth in cardiovascular and diabetes tech.

Medtronic (MDT) to report Q4 2026 results on 6/3, expected revenue of $9.61B & EPS of $1.55. Recent acquisition of SPR Therapeutics adds to neuromodulation business. Analyst…

Medtronic to report Q4 2026 results with expected revenue of $9.61B and EPS of $1.55. Dividend yield is 3.83%.

Medtronic Plc (MDT) is currently at $77.42, up $3.67 or 4.98%

Irish-headquartered medtech giant working through spin out of diabetes business and focus on smaller, targeted acquisitions

Medtronic (MDT) stock jumps after beating Q4 revenue expectations, driven by strong growth in cardiovascular and diabetes tech.